Australian Court Rules Formulation Patents Ineligible for Patent Term Extensions in Landmark Otsuka Decision
核心洞察
The Full Court of the Federal Court of Australia ruled that only patents claiming active pharmaceutical ingredients are eligible for patent term extensions, not pharmaceutical formulations.
The decision in Otsuka Pharmaceutical Co Ltd v Sun Pharma ANZ Pty Ltd invalidates existing patent term extensions for formulation patents, creating "zombie PTEs" vulnerable to challenge.
Pharmaceutical companies must urgently review their patent portfolios as the ruling affects loss of exclusivity dates and may accelerate generic drug market entry across Australia.
The Full Court of the Federal Court of Australia has delivered a seismic ruling that fundamentally reshapes Australia's pharmaceutical patent landscape, holding that formulation patents are no longer eligible for patent term extensions (PTEs). The unanimous decision in Otsuka Pharmaceutical Co Ltd v Sun Pharma ANZ Pty Ltd [2025] FCAFC 161, published December 4, 2025, restricts PTEs exclusively to patents claiming active pharmaceutical ingredients.
Court Overturns Established Practice
The landmark ruling overturns years of Australian Patent Office practice that allowed patent term extensions for "novel and inventive formulations of known drugs." The Full Court concluded that the term "pharmaceutical substance" in Australia's patent legislation refers only to active ingredients, not formulations combining active ingredients with excipients.
Justice Downes at first instance had followed the precedent in Cipla Australia Pty Ltd v Novo Nordisk A/S, allowing formulation patents to receive separate PTEs. However, the Full Court rejected this interpretation after completing "a detailed review of the history and judicial treatment of 'pharmaceutical substance.'"
Aripiprazole Case Details
The dispute centered on Otsuka's patent for controlled release injectable aripiprazole formulations (ABILIFY MAINTENA), used to treat schizophrenia (搜索). Otsuka had obtained a patent term extension in 2015, extending the patent term until July 25, 2029, based on regulatory approval delays for the monthly depot formulation. The product generates significant revenue, with PBS reimbursements exceeding A$56 million in the 2024/25 financial year.
Sun Pharma challenged the PTE to clear the path for launching its generic monthly aripiprazole depot product (ARIPENA (搜索)). The company argued that only the active ingredient aripiprazole, first patented in 1991 and listed on the Australian Register of Therapeutic Goods in May 2003, should be considered the relevant pharmaceutical substance.
Legislative Interpretation and Rationale
The Full Court traced the legislative history back to the Patents Amendment Bill 1989, finding that the original definition was "limited to patents for active ingredients only." The court noted that while earlier customs regulations included formulations, the 1989 bill expressly limited the concept to substances involving "a chemical interaction, or physico-chemical interaction, with a human physiological system."
The decision aligns with the PTE regime's underlying purpose: providing extended monopolies justified by "the significant time and cost required to achieve regulatory approval of new active ingredients." The court observed that developing new formulations of existing active ingredients is "less time consuming, and less costly" than developing entirely new compounds.
Multiple Grounds for PTE Invalidity
Beyond the primary ruling on pharmaceutical substances, the Full Court upheld Sun Pharma's additional arguments against the PTE. These included findings that freeze-dried formulations cannot constitute pharmaceutical substances because they are never administered in the claimed form, requiring reconstitution into liquid before injection.
The court also determined that the relevant ARTG goods did not contain the claimed controlled release formulation, as they consisted of separate vials of freeze-dried powder and water rather than a ready-to-inject liquid formulation.
Industry-Wide Implications
The decision creates numerous "zombie PTEs" - previously granted patent term extensions that are now vulnerable to challenge. Companies holding formulation patents with existing PTEs face immediate exposure, while generic manufacturers can accelerate market entry timelines.
The Australian Patent Office has two mechanisms for removing invalid PTEs: the Commissioner of Patents can proactively remove them under section 191A of the Patents Act 1990, or third parties can apply for removal under sections 191A or 192. Whether the Patent Office will proactively cancel zombie PTEs or leave identification to third parties remains unclear.
Expected Appeal and Timeline
Industry observers expect Otsuka to seek special leave to appeal to the High Court of Australia, with the deadline falling in early January 2026. However, recent precedent suggests challenges, as the High Court refused special leave in two recent pharmaceutical patent cases: Sandoz v Bayer (rivaroxaban) and Pharmacor (搜索) v Novartis (sacubitril/valsartan).
Immediate Industry Response
Pharmaceutical companies are urgently reviewing patent portfolios and revising loss of exclusivity dates across Australia. Generic and biosimilar manufacturers are accelerating market entry preparations and filing low-cost rectification applications where originator exclusivity previously relied on formulation patent extensions.
The ruling represents the first Full Federal Court challenge on formulation patent eligibility for PTEs, establishing binding precedent that will reshape pharmaceutical patent strategy in Australia. While formulation patents remain eligible for standard 20-year patent protection, they can no longer benefit from the additional five-year extension previously available.